サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：分子腫瘍診断市場- 世界の産業規模、シェア、動向、競合、機会、および予測、2018-2028年
市場調査レポート
商品コード
1309227

分子腫瘍診断市場- 世界の産業規模、シェア、動向、競合、機会、および予測、2018-2028年

Molecular Oncology Diagnostics Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2018-2028 Segmented By Product Type, By Technology, By Application, By Cancer Type, By End User, By Region
出版日: | 発行: TechSci Research | ページ情報: 英文 111 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.13円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

分子腫瘍診断市場- 世界の産業規模、シェア、動向、競合、機会、および予測、2018-2028年
出版日: 2023年07月01日
発行: TechSci Research
ページ情報: 英文 111 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

世界の分子腫瘍診断市場は、予測期間2024～2028年に安定したCAGRを記録すると予測されています。

この背景には、がん、心血管疾患、糖尿病など、さまざまな慢性疾患の有病率が上昇していることがあります。Global Cancer Observatoryによると、2020年には世界中で約19,292,789件の新規がん症例が報告され、そのうち男性は10,065,305件、女性は9,227,484件でした。がんは、がん細胞の無秩序な増殖によって引き起こされ、その増殖は内膜から外膜へと広がっていく。分子腫瘍診断学とは、がんを診断するための検査を指します。これらの検査は、遺伝物質、タンパク質、または関連化学物質を同定し、健康や病気に関する情報を提供するために使用されます。しかし、新たな診断方法や機器の開発が必要であり、これが分子腫瘍診断市場の成長をさらに促進すると予想されます。

がんの有病率の上昇

がんは世界で最も一般的な死因の一つです。がん患者の世界の増加が、分子腫瘍診断市場の成長要因であろう。米国がん協会によると、2021年の米国では、新たにがんに罹患した患者数は180万人、がんによる死亡者数は60万人でした。がん細胞の増殖により、医療関係者はがんの予防と治療を助ける治療法や診断サービスを開発するための研究開発努力を強めています。米国がん協会によると、肺がん、前立腺がん、腸がん、女性乳がんは世界的に上位4つのがん種を占め、新規がん症例の43％を占めています。例えば、米国がん協会は、2022年までに米国で結腸がんが106,180例、直腸がんが44,850例新たに発生すると推定しています。さらに、米国がん学会の2020年報告書によれば、全米総合がんネットワーク（NCCN）、米国臨床腫瘍学会（ASCO）、米国病理学会（CAP）など複数の専門家団体がバイオマーカー検査や治療ガイドラインを策定しています。したがって、これらの治療や画像診断が、世界の分子腫瘍診断市場の成長を促進する要因となっています。

技術の進歩

先進技術はゲノミクスのシーケンス技術を構成します。例えば、がんゲノムシーケンス技術の進歩、計算解析、腫瘍モデル、最新のがん研究機関で行われている技術革新や研究は、がんやその変異の早期発見を促進します。例えば、2020年6月、米国食品医薬品局（FDA）は、非小細胞肺がん患者を検査するための変異検査であるコバスEGFR変異検査に承認を与えました。この検査は、上皮成長因子受容体をコードするEGFR遺伝子のがん耐性変異と42の変異を同定できるリアルタイム検査です。この分子検査は米国のRoche Molecular Systems社によって開発されました。

最近の開発と製品上市

がんのような生命を脅かす様々な疾患の治療のための新規診断ソリューション開発の必要性が高まっていることから、研究開発（R&D）の実践と活動における急速な進歩が市場の成長を後押ししています。例えば、2022年8月にGuardant Health社はGuardant Reveal検査の用途を拡大し、早期乳がんや肺がんなどの残存病変検出や再発モニタリングのためのリキッドバイオプシー検査を開発しました。この検査は現在、乳がんや肺がんの患者が利用可能で、大腸がん（CRC）については組織を用いない唯一の検査です。

さらに2021年12月、QIAGENはDenovo Biopharma社との提携により、びまん性大細胞型B細胞リンパ腫の治療のためのコンパニオン診断検査を開発しました。この検査では、Denovoの抗がん剤DB102に反応するDenovoゲノムマーカー1（DGM1）を持つ人を特定しました。

利用可能なカスタマイズ

TechSci Researchは、与えられた市場データを用いて、企業の特定のニーズに応じてカスタマイズを提供します。レポートでは以下のカスタマイズが可能です：

企業情報

  • 追加市場参入企業（最大5社）の詳細分析とプロファイリング

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 分子腫瘍診断の世界市場展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • 製品タイプ別（装置、キットおよびアッセイ、ソフトウェア）
    • 技術別（蛍光 In-Situ ハイブリダイゼーション（FISH）、次世代シーケンシング（NGS）、ポリメラーゼ連鎖反応（PCR）、免疫組織化学（IHC）、フローサイトメトリー、その他技術）
    • 用途別（調査、臨床）
    • がんタイプ別｛固形がん（乳がん、卵巣がん、前立腺がん、肺がん、大腸がん、その他固形がん）、血液がん（リンパ腫、白血病、多発性骨髄腫、その他血液悪性腫瘍）
    • エンドユーザー別（病院・診断センター、リファレンスラボ、製薬・バイオテクノロジー企業、学術・研究機関）
    • 地域別（北米、欧州、アジア太平洋、南米、中東・アフリカ）
    • 企業別（2022年）
  • 市場マップ
    • 製品タイプ別
    • 技術別
    • 用途別
    • がんタイプ別
    • エンドユーザー別
    • 地域別

第6章 北米の分子腫瘍診断市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 製品タイプ別
    • 技術別
    • 用途別
    • がんタイプ別
    • エンドユーザー別
    • 国別
  • 北米国別分析
    • 米国
    • カナダ
    • メキシコ

第7章 欧州の分子腫瘍診断市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • 製品タイプ別
    • 技術別
    • 用途別
    • がんタイプ別
    • エンドユーザー別
    • 国別
  • 欧州国別分析
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン

第8章 アジア太平洋地域の分子腫瘍診断薬市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • 製品タイプ別
    • 技術別
    • 用途別
    • がんタイプ別
    • エンドユーザー別
    • 国別
  • アジア太平洋地域国別分析
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア

第9章 南米の分子腫瘍診断市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • 製品タイプ別
    • 技術別
    • 用途別
    • がんタイプ別
    • エンドユーザー別
    • 国別
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの分子腫瘍診断市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • 製品タイプ別
    • 技術別
    • 用途別
    • がんタイプ別
    • エンドユーザー別
    • 国別
  • MEA：国別分析
    • アラブ首長国連邦
    • サウジアラビア
    • 南アフリカ

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

第13章 競合情勢

  • Business Overview
  • Product Offerings
  • Recent Developments
  • Financials（As Reported）
  • Key Personnel
    • Sysmex Corporation
    • F. Hoffmann-La Roche Ltd.
    • Myriad Genetics, Inc.
    • HTG Molecular Diagnostics, Inc.
    • Danaher Corporation.
    • QIAGEN N.V.
    • Bio-Rad Laboratories, Inc.
    • Agilent Technologies, Inc.
    • QIAGEN N.V.
    • Illumina, Inc.

第14章 戦略的提言

目次
Product Code: 15019

Global Molecular Oncology Diagnostics Market is anticipated to witness a steady CAGR in the forecast period, 2024-2028. This can be ascribed to the rising prevalence of various chronic diseases such as cancer, cardiovascular diseases, and diabetes, among others. According to Global Cancer Observatory, in 2020, around 19,292,789 new cancer cases were reported worldwide, among which the males and females accounted for 10,065,305 and 9 227,484 cases, respectively. Cancer is caused due to uncontrolled proliferation of cancer cells that starts from the inner lining to the outer region. Molecular oncology diagnostics refers to the tests for diagnosing cancer. These tests are used to identify the genetic material, proteins, or associated chemicals and provide information on health or disease. However, there is a need for developing new diagnostic methods and instruments, which is further expected to drive the growth of the Molecular Oncology Diagnostics Market.

The growing prevalence of cancer cases, the advanced technological advancement with the highest accuracy and precision, and the growing awareness amongst the population globally are projected to propel the growth of the market. Additionally, the high cost of molecular diagnostic techniques is expected to hamper the growth of the Global Molecular Oncology Diagnostics Market in the forecast years.

Rising Prevalence of Cancer

Cancer is one of the most common causes of death in the world. The global increase in cancer cases is probably a factor in the oncology molecular diagnostics market's growth. In the United States of America in 2021, there were 1.8 million new instances of cancer and 0.6 million cancer deaths, according to the American Cancer Society. Due to the proliferation of cancerous cells, medical professionals are increasing their research and development efforts to develop treatments and diagnostics services to aid the prevention and treatment of cancer. Lung, prostate, bowel, and female breast cancer make up the top four cancer types worldwide, accounting for 43% of all new cancer cases, according to the American Cancer Society. For instance, the American Cancer Society estimates that there will be 106,180 new instances of colon cancer and 44,850 new cases of rectal cancer in the United States by the year 2022. Additionally, several professional associations, including the National Comprehensive Cancer Network (NCCN), the American Association of Clinical Oncology (ASCO), and the College of American Pathologists (CAP), have developed biomarker testing and treatment guidelines, according to the American Cancer Society's 2020 report. Therefore, their treatment or diagnostic imaging is responsible for propelling the growth of Global Molecular Oncology Diagnostic Market.

Advancement in Technology

The advanced technology constitutes the sequencing techniques of genomics. For instance, the advancement in cancer genome sequencing technology, computational analysis, tumor models, and innovation and research going on in modern cancer research institutes promote early detection of cancer and its mutation. For instance, in June 2020, the United States Food and Drug Administration (FDA) gave approval to Cobas EGFR Mutation Test, a mutation test for testing patients with non-small cell lung cancer is a real-time test that can identify cancer resistance mutations and 42 mutations in the EGFR gene, which codes for the epidermal growth factor receptor. This molecular test was developed by a US-based company, namely Roche Molecular Systems, Inc.

Recent Developments & Product Launches

Rapid advancements in research and development (R&D) practices and activities are propelling the growth of the market on account of the growing need for developing novel diagnostic solutions for the treatment of different life-threatening diseases like cancer. For instance, in August 2022, Guardant Health expanded its Guardant Reveal test usage and developed a liquid biopsy test for residual disease detection and recurrence monitoring, including early-stage breast and lung cancers. It is currently accessible to patients with breast and lung cancer and is the only tissue-free test for colorectal cancer (CRC).

Additionally, in December 2021, QIAGEN, in partnership with Denovo Biopharma, developed a companion diagnostic test for the treatment of diffuse large B-cell lymphoma. This test identified people who have the Denovo genomic marker 1 (DGM1), which responded to the Denovo cancer drug DB102.

Market Segmentation

Global Molecular Oncology Diagnostics Market can be segmented by product type, technology, application, cancer type, end user, region, and company. Based on product type, the market can be segmented into instruments, kits and assays, and software. Based on technology, the market is fragmented into fluorescence in-situ hybridization (FISH), next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), flow cytometry, and other technologies. Based on application, the market is fragmented into Research and Clinical. Based on cancer type, the market is fragmented into solid tumors and blood cancers. Based on end users, the market is segmented into hospitals and diagnostic centers, reference laboratories, pharmaceutical and biotechnology companies, and academic and research institutes.

Advancement in Technology and Product Launch

The market players in Global Molecular Oncology Diagnostics Market are adopting various natural and modified strategies for market growth and development. For instance, a 5-year extension of their US supply agreement for the Insured ONE (FIT) fecal immunochemistry test was announced in January 2022 by Clinical Genomics, an innovator in the development of colorectal cancer testing, and Quest Diagnostics (NYSE: DGX), the world's largest provider of diagnostic information services. By delivering InSure FIT and the new InSure ONE FIT for colorectal cancer diagnostic programs, this arrangement improves an ongoing partnership. Amgen and Plexium established a multi-year partnership to find new targeted protein degradation treatments in February 2022. The multi-year partnership aids in the development of innovative molecular glue therapies by utilizing knowledge gained from Amgen's experience in creating multi-specific compounds. Furthermore, several strategies like collaboration, partnerships, mergers, acquisitions, product launches, and technology development propel the growth of Global Molecular Oncology Diagnostic Market.

Company Profiles

Sysmex Corporation, F. Hoffmann-La Roche Ltd., Myriad Genetics, Inc., HTG Molecular Diagnostics, Inc., Danaher Corporation, QIAGEN N.V., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., QIAGEN N.V., Illumina, Inc., etc. are some of the key players operating in the global molecular oncology diagnostics market.

Report Scope

In this report, Global Molecular Oncology Diagnostics Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Molecular Oncology Diagnostics Market, By Product Type:

  • Instruments
  • Kits and Assays
  • Software

Molecular Oncology Diagnostics Market, By Technology:

  • Fluorescence In-Situ Hybridization (FISH)
  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • Flow Cytometry
  • Other Technologies

Molecular Oncology Diagnostics Market, By Application:

  • Research
  • Clinical

Molecular Oncology Diagnostics Market, By Cancer Type:

  • Solid Tumor
    • Breast Cancer
    • Ovarian Cancer
    • Prostate Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Other
  • Blood Cancers
    • Lymphoma
    • Leukemia
    • Multiple Myeloma
    • Others

Molecular Oncology Diagnostics Market, By End User:

  • Hospitals and Diagnostic Centers
  • Reference Laboratories
  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes

Molecular Oncology Diagnostics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • South Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Molecular Oncology Diagnostics Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Molecular Oncology Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Instruments, Kits and Assays, Software)
    • 5.2.2. By Technology (Fluorescence In-Situ Hybridization (FISH), Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Flow Cytometry, and Other Technologies)
    • 5.2.3. By Application (Research, Clinical)
    • 5.2.4. By Cancer Type {Solid Tumor (Breast Cancer, Ovarian Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, and Other Solid Tumors), Blood cancers (Lymphoma, Leukemia, Multiple Myeloma, and other Hematological Malignancies)}
    • 5.2.5. By End User (Hospitals and Diagnostic Centers, Reference Laboratories, Pharmaceutical and Biotechnology Companies, Academic and Research Institutes)
    • 5.2.6. By Region (North America, Europe, Asia Pacific, South America, Middle East, and Africa)
    • 5.2.7. By Company (2022)
  • 5.3. Market Map
    • 5.3.1. By Product Type
    • 5.3.2. By Technology
    • 5.3.3. By Application
    • 5.3.4. By Cancer Type
    • 5.3.5. By End User
    • 5.3.6. By Region

6. North America Molecular Oncology Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Technology
    • 6.2.3. By Application
    • 6.2.4. By Cancer Type
    • 6.2.5. By End User
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Molecular Oncology Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By Cancer Type
        • 6.3.1.2.5. By End User
    • 6.3.2. Canada Molecular Oncology Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By Cancer Type
        • 6.3.2.2.5. By End User
    • 6.3.3. Mexico Molecular Oncology Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By Cancer Type
        • 6.3.3.2.5. By End User

7. Europe Molecular Oncology Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Technology
    • 7.2.3. By Application
    • 7.2.4. By Cancer Type
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Molecular Oncology Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By Cancer Type
        • 7.3.1.2.5. By End User
    • 7.3.2. France Molecular Oncology Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By Cancer Type
        • 7.3.2.2.5. By End User
    • 7.3.3. United Kingdom Molecular Oncology Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By Cancer Type
        • 7.3.3.2.5. By End User
    • 7.3.4. Italy Molecular Oncology Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By Cancer Type
        • 7.3.4.2.5. By End User
    • 7.3.5. Spain Molecular Oncology Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By Cancer Type
        • 7.3.5.2.5. By End User

8. Asia-Pacific Molecular Oncology Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Technology
    • 8.2.3. By Application
    • 8.2.4. By Cancer Type
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Molecular Oncology Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By Cancer Type
        • 8.3.1.2.5. By End User
    • 8.3.2. Japan Molecular Oncology Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By Cancer Type
        • 8.3.2.2.5. By End User
    • 8.3.3. India Molecular Oncology Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By Cancer Type
        • 8.3.3.2.5. By End User
    • 8.3.4. South Korea Molecular Oncology Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By Cancer Type
        • 8.3.4.2.5. By End User
    • 8.3.5. Australia Molecular Oncology Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By Cancer Type
        • 8.3.5.2.5. By End User

9. South America Molecular Oncology Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Technology
    • 9.2.3. By Application
    • 9.2.4. By Cancer Type
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Molecular Oncology Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By Cancer Type
        • 9.3.1.2.5. By End User
    • 9.3.2. Argentina Molecular Oncology Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By Cancer Type
        • 9.3.2.2.5. By End User
    • 9.3.3. Colombia Molecular Oncology Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By Cancer Type
        • 9.3.3.2.5. By End User

10. Middle East and Africa Molecular Oncology Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Technology
    • 10.2.3. By Application
    • 10.2.4. By Cancer Type
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. UAE Molecular Oncology Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By Cancer Type
        • 10.3.1.2.5. By End User
    • 10.3.2. Saudi Arabia Molecular Oncology Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By Cancer Type
        • 10.3.2.2.5. By End User
    • 10.3.3. South Africa Molecular Oncology Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By Cancer Type
        • 10.3.3.2.5. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

13. Competitive Landscape

  • 13.1. Business Overview
  • 13.2. Product Offerings
  • 13.3. Recent Developments
  • 13.4. Financials (As Reported)
  • 13.5. Key Personnel
    • 13.5.1. Sysmex Corporation
    • 13.5.2. F. Hoffmann-La Roche Ltd.
    • 13.5.3. Myriad Genetics, Inc.
    • 13.5.4. HTG Molecular Diagnostics, Inc.
    • 13.5.5. Danaher Corporation.
    • 13.5.6. QIAGEN N.V.
    • 13.5.7. Bio-Rad Laboratories, Inc.
    • 13.5.8. Agilent Technologies, Inc.
    • 13.5.9. QIAGEN N.V.
    • 13.5.10. Illumina, Inc.

14. Strategic Recommendations